Department of Microbiology and Immunology, University of North Carolina (UNC) School of Medicine, Chapel Hill, NC 27514, USA; University of North Carolina HIV Cure Center, Institute of Global Health and Infectious Diseases, Chapel Hill, NC 27514, USA.
University of North Carolina HIV Cure Center, Institute of Global Health and Infectious Diseases, Chapel Hill, NC 27514, USA.
Cell Chem Biol. 2023 Dec 21;30(12):1617-1633.e9. doi: 10.1016/j.chembiol.2023.11.009.
A long-lived latent reservoir of HIV-1-infected CD4 T cells persists with antiretroviral therapy and prevents cure. We report that the emergence of latently infected primary CD4 T cells requires the activity of histone deacetylase enzymes HDAC1/2 and HDAC3. Data from targeted HDAC molecules, an HDAC3-directed PROTAC, and CRISPR-Cas9 knockout experiments converge on a model where either HDAC1/2 or HDAC3 targeting can prevent latency, whereas all three enzymes must be targeted to achieve latency reversal. Furthermore, HDACi treatment targets features of memory T cells that are linked to proviral latency and persistence. Latency prevention is associated with increased H3K9ac at the proviral LTR promoter region and decreased H3K9me3, suggesting that this epigenetic switch is a key proviral silencing mechanism that depends on HDAC activity. These findings support further mechanistic work on latency initiation and eventual clinical studies of HDAC inhibitors to interfere with latency initiation.
抗逆转录病毒治疗可使 HIV-1 感染的 CD4 T 细胞长期潜伏,并阻止治愈。我们报告称,潜伏感染的原发性 CD4 T 细胞的出现需要组蛋白去乙酰化酶 HDAC1/2 和 HDAC3 的活性。来自靶向 HDAC 分子、一种靶向 HDAC3 的 PROTAC 和 CRISPR-Cas9 基因敲除实验的数据汇聚成一个模型,即靶向 HDAC1/2 或 HDAC3 可以预防潜伏,而必须靶向所有三种酶才能实现潜伏逆转。此外,HDACi 治疗针对与前病毒潜伏和持续相关的记忆 T 细胞特征。潜伏期预防与前病毒 LTR 启动子区域的 H3K9ac 增加和 H3K9me3 减少有关,这表明这种表观遗传开关是一个关键的前病毒沉默机制,依赖于 HDAC 活性。这些发现支持进一步研究潜伏启动的机制,并最终开展 HDAC 抑制剂的临床研究,以干扰潜伏的启动。